Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 754132 in Geographic Atrophy
NCT04002310Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BI 754132 in geographic atrophy (GA) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With Ocular or Systemic Dose Limiting Events at Day 100 and Number of Patients With Drug Related Adverse Events at Day 155. Started Jul 2019; status: terminated.
02
Drugs
BI 754132
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04002310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002310.